Concomitant Chemoradiotherapy and Targeted Therapy in Glioblastoma Multiforme


Authors: P. Burkoň 1*;  R. Lakomý 2*;  D. Burkoňová 1;  P. Fadrus 3
Authors‘ workplace: Oba autoři přispěli k práci stejným dílem *;  Klinika radiační onkologie LF MU a MOÚ, Brno 1;  Klinika komplexní onkologické péče, LF MU a MOÚ, Brno 2;  Neurochirurgická klinika LF MU a FN Brno 3
Published in: Cesk Slov Neurol N 2010; 73/106(5): 503-509
Category: Review Article

Overview

Glioblastoma multiforme (GBM) is among the most aggressive of malignant brain tumors and therapeutic options for it are limited. Standard therapy is maximal surgical resection and adjuvant concurrent chemoradiotherapy and maintenance therapy with temozolomid. This approach improves median and 5-year survival in comparison with postsurgical radiotherapy alone. MGMT (O6-Methylguanine-DNA-methyltransferase) promoter methylation is the first predictive biomarker. Low levels of expression of MGMT protein are correlated with successful treatment. Additional predictive and prognostic biomarkers are required, especially in the light of the development of targeted therapy – antibodies and tyrosine kinase inhibitors. New therapeutic approaches are under intensive investigation. The most promising data currently derive from anti-angiogenic therapies, such as bevacizumab and cediranib. This review presents a summary covering chemotherapy, the significance of promoter methylation MGMT, pseudoprogression and the possible role of targeted therapy in the treatment of glioblastoma multiforme.

Key words:
glioblastoma multiforme – chemotherapy – biomarkers – angiogenesis


Sources

1. Walker MD, Green SB, Byar DP, Alexander E jr, Batzdorf U, Brooks WH et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303(23): 1323–1329.

2. Kala M, Cwiertka K, Hajdúch M. Nové trendy v chemoterapii nádorů mozku – léčba dle histologic­kých diagnóz. Klin Onkol 2000; 13(4): 107–111.

3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71(8): 2585–2597.

4. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359(9311): 1011–1018.

5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987–996.

6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5): ­459–466.

7. Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A et al. A prospective study on glioblastoma in elderly. Cancer 2003; 97(3): 657–662.

8. Mirimanoff R, Mason W, van den Bent M, ­Kortmann R, Taphoorn M, Brandes A et al. Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus RT alone. Int J Radiat Oncol Biol Phys 2007; 69 (3 Suppl): S2.

9. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de ­Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997–1003.

10. Esteller M, Garcia-Foncillas J, Andion E, ­Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343(19): 1350–1354.

11. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regil L, Ostermann S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin ­Cancer Res 2004; 10(6): 1871–1874.

12. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10(15): 4933–4938.

13. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanism and management of pseudoprogression in malignant gliomas. Lancet 2008; 9(5): 453–461.

14. Nečesalová E, Kuglík P, Cejpek P, Veselská R, ­Vranová R, Pešáková M et al. Studium polyzomie chromozomu 7, monozomie chromozomu 10, amplifikace genu EGFR a delece genu p53 u multiformního glioblastomu pomocí metody fluorescenční in situ hybri­dizace (FISH). Klin Onkol 2006; 19(1): 9–14.

15. Folkman J. Tumor angiogenesis : therapeutic implications. N Engl J Med 1971; 285(21): 1182–1186.

16. Jain RK. Normalizing tumor vasculature with ­anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7(9): 987–989.

17. Glass J, Gruber LM, Nirenberg A. Phase II trial of the antiangiogenic agen thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 1999; 18 (Suppl): 144.

18. Vredenburgh JJ, Desjardins A, Herndon JE, ­Marcello J, Reardon DA, Quinn JA et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722–4729.

19. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28): 4733–4740.

20. Radiation Therapy Oncology Group 0825, Ameri­can College of Radiology. Phase III double-blind ­placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma [online]. September 29, 2009 [cited 2010 Jan 20]. Dostupné z URL: http://www.rtog.org/members/protocols/0825/0825.pdf.

21. Batchelor T, Sorensen AG, Ancukiewicz M, Duda DG, Luis DN, Plotkin SR et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with relapsed glioblastoma. J Clin Oncol 2007; 25 (Suppl): abstr. 2001.

22. Neyns B, Sadones J, Joosens E, Bouttens F, ­Verbeke L, Baurain JF et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009; 20(9): 1596–1603.

23. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22(1): 133–142.

24. Vogelbaum MA, Peereboom D, Stevens GH, ­Barnett GH, Brewer C. Phase II study of single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme. Ann Oncol 2004; 15 (Suppl 3): iii206.

25. Chakravarti A, Seiferheld W, Tu X, Wang H, Zhang HZ, Ang KK et al. Immunohistochemically determined total epidermal growth factor receptor ­levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62(2): 318–327.

26. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin Cancer Res 2006; 12(16): 4899–4907.

27. Van den Bent M, Brandes A, Frenay M, Fumoleau P, Stupp R, Dittrich C et al. Multicentre phase II study of imatinib mesylate (Glivec®) in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): an EORTC New Drug Deve­lopment Group (NDDG) and Brain Tumor Group (BTG) study. J Clin Oncol 2005; 23 (Suppl): 1517.

28. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2005; 23(23): 5294–5304.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 5

2010 Issue 5

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account